• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Medline Inc.

    2/11/26 4:23:03 PM ET
    $MDLN
    Medical/Dental Instruments
    Health Care
    Get the next $MDLN alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    Medline Inc.

    (Name of Issuer)


    Class A Common Stock, par value $0.0001 per share

    (Title of Class of Securities)


    58507V107

    (CUSIP Number)


    12/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    58507V107


    1Names of Reporting Persons

    Abu Dhabi Investment Authority
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED ARAB EMIRATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    517,241.00
    6Shared Voting Power

    46,998,036.00
    7Sole Dispositive Power

    517,241.00
    8Shared Dispositive Power

    46,998,036.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    47,515,277.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.9 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  (1) Abu Dhabi Investment Authority is the direct owner of 517,241 of the shares of Class A Common Stock represented herein. (2) The percent calculation is based on 811,418,179 shares of Class A Common Stock outstanding as of December 18, 2025 as reported in Medline Inc.'s prospectus filed pursuant to Rule 424(b)(4) with the Securities and Exchange Commission on December 18, 2025.


    SCHEDULE 13G

    CUSIP No.
    58507V107


    1Names of Reporting Persons

    Platinum Falcon B 2018 RSC Limited
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED ARAB EMIRATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    46,998,036.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    46,998,036.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    46,998,036.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.8 %
    12Type of Reporting Person (See Instructions)

    CO

    Comment for Type of Reporting Person:  (1) Platinum Falcon B 2018 RSC Limited ("Platinum Falcon") is the direct owner of 46,998,036 of the shares of Class A Common Stock reported herein. Platinum Falcon is a wholly owned subsidiary of Abu Dhabi Investment Authority. Pursuant to the rules and regulations of the Securities and Exchange Commission, Abu Dhabi Investment Authority may be deemed to be the beneficial owner of the shares of Class A Common Stock directly held by Platinum Falcon. (2) The percent calculation based on 811,418,179 shares of Class A Common Stock outstanding as of December 18, 2025 as reported in Medline Inc.'s prospectus filed pursuant to Rule 424(b)(4) with the Securities and Exchange Commission on December 18, 2025.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Medline Inc.
    (b)Address of issuer's principal executive offices:

    3 Lakes Drive, Northfield, IL 60093
    Item 2. 
    (a)Name of person filing:

    This Schedule 13G is being filed on behalf of the following: 1. Abu Dhabi Investment Authority 2. Platinum Falcon B 2018 RSC Limited
    (b)Address or principal business office or, if none, residence:

    1. 211 Corniche Street P.O. Box 3600 Abu Dhabi, United Arab Emirates 3600 2. Level 26, Al Khatem Tower Abu Dhabi Global Market Square Al Maryah Island, Abu Dhabi United Arab Emirates
    (c)Citizenship:

    1. Abu Dhabi Investment Authority (ADIA) is a public institution established by the Government of the Emirate of Abu Dhabi in 1976 as an independent investment institution. ADIA is a public institution. 2. Platinum Falcon B 2018 RSC Limited is a restricted scope company organized under the laws of the Abu Dhabi Global Market, Abu Dhabi, United Arab Emirates.
    (d)Title of class of securities:

    Class A Common Stock, par value $0.0001 per share
    (e)CUSIP No.:

    58507V107
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    See responses to Item 9 on each cover page.
    (b)Percent of class:

    See responses to Item 11 on each cover page.
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    See responses to Item 5 on each cover page.

     (ii) Shared power to vote or to direct the vote:

    See responses to Item 6 on each cover page.

     (iii) Sole power to dispose or to direct the disposition of:

    See responses to Item 7 on each cover page.

     (iv) Shared power to dispose or to direct the disposition of:

    See responses to Item 8 on each cover page.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Not Applicable
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    Not Applicable

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Abu Dhabi Investment Authority
     
    Signature:/s/ Saif Surour Omair Maaded AlMashghouni
    Name/Title:Saif Surour Omair Maaded AlMashghouni/Authorized Signatory
    Date:02/11/2026
     
    Signature:/s/ Ahmed Salem Abdulla Melaih AlNeyadi
    Name/Title:Ahmed Salem Abdulla Melaih AlNeyadi/Authorized Signatory
    Date:02/11/2026
     
    Platinum Falcon B 2018 RSC Limited
     
    Signature:/s/ Saif Surour Omair Maaded AlMashghouni
    Name/Title:Saif Surour Omair Maaded AlMashghouni/Authorized Signatory
    Date:02/11/2026
     
    Signature:/s/ Ahmed Salem Abdulla Melaih AlNeyadi
    Name/Title:Ahmed Salem Abdulla Melaih AlNeyadi/Authorized Signatory
    Date:02/11/2026
    Exhibit Information

    Exhibit 1: Joint Filing Agreement

    Get the next $MDLN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MDLN

    DatePrice TargetRatingAnalyst
    2/5/2026$55.00Buy
    Tigress Financial
    1/21/2026$50.00 → $55.00Buy
    BTIG Research
    1/12/2026$48.00Buy
    Citigroup
    1/12/2026$38.00Neutral
    BNP Paribas Exane
    1/12/2026$50.00Overweight
    Analyst
    1/12/2026$50.00Overweight
    Piper Sandler
    1/12/2026$48.00Overweight
    Morgan Stanley
    1/12/2026$47.00Outperform
    RBC Capital Mkts
    More analyst ratings

    $MDLN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Gic Private Ltd sold $289,480,090 worth of shares (10,204,351 units at $28.37) and bought $364,999,974 worth of shares (12,586,206 units at $29.00) (SEC Form 4)

    4 - Medline Inc. (0002046386) (Issuer)

    12/22/25 5:26:57 PM ET
    $MDLN
    Medical/Dental Instruments
    Health Care

    Director Mills Andrew J. was granted 30,655 units of Class B Common Stock and bought $74,999,974 worth of shares (2,586,206 units at $29.00) (SEC Form 4)

    4 - Medline Inc. (0002046386) (Issuer)

    12/22/25 4:30:06 PM ET
    $MDLN
    Medical/Dental Instruments
    Health Care

    Director Mills Charles N. was granted 64,005 units of Class B Common Stock and bought $74,799,990 worth of shares (2,579,310 units at $29.00) (SEC Form 4)

    4 - Medline Inc. (0002046386) (Issuer)

    12/22/25 4:30:04 PM ET
    $MDLN
    Medical/Dental Instruments
    Health Care

    $MDLN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Medline to report fourth quarter and full year 2025 results on February 25, 2026

    NORTHFIELD, Ill., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Medline Inc. ("Medline") (NASDAQ:MDLN) today announced that it plans to report fourth quarter and full year 2025 financial results on Wednesday, February 25, 2026. A press release and supplemental materials will be issued before the market opens. The company will host a webcast and conference call at 9:30am ET/ 8:30am CT to discuss the financial results. Information about Medline's financial results, including a link to the live webcast, will be available on the Events page of Medline's Investor Relations website at ir.medline.com. A replay of the webcast will be available following the event through the same website. About MedlineMedli

    1/28/26 9:00:00 AM ET
    $MDLN
    Medical/Dental Instruments
    Health Care

    Medline Announces Participation in J.P. Morgan 2026 Healthcare Conference

    NORTHFIELD, Ill., Dec. 30, 2025 (GLOBE NEWSWIRE) -- Medline Inc. ("Medline") (NASDAQ:MDLN) today announced that Jim Boyle, Chief Executive Officer, and Mike Drazin, Chief Financial Officer, are scheduled to present at the J.P. Morgan Healthcare Conference in San Francisco, Calif., on Tuesday, January 13, 2026, at 3:00 pm Pacific Time. The presentation will be available on the Events page of Medline's Investor Relations website at ir.medline.com. A replay of the webcast will be available on Medline's Investor Relations website for 30 days following the event. About MedlineMedline is the largest provider of medical-surgical ("med-surg") products and supply chain solutions serving all point

    12/30/25 4:05:00 PM ET
    $MDLN
    Medical/Dental Instruments
    Health Care

    Medline Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

    NORTHFIELD, Ill., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Medline Inc. (NASDAQ:MDLN) ("Medline") announced today that it has closed its upsized initial public offering of 248,439,654 shares of its Class A common stock at a public offering price of $29.00 per share, including the full exercise by the underwriters of their option to purchase up to an additional 32,405,172 shares of Class A common stock. Medline intends to use the proceeds (net of underwriting discounts) from the issuance of 179,000,000 shares to repay outstanding indebtedness under its senior secured term loan facilities and the remainder for general corporate purposes and to bear the expenses of the offering. Medline intends to

    12/18/25 4:05:00 PM ET
    $MDLN
    Medical/Dental Instruments
    Health Care

    $MDLN
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Medline Inc.

    SCHEDULE 13G - Medline Inc. (0002046386) (Subject)

    2/11/26 4:23:03 PM ET
    $MDLN
    Medical/Dental Instruments
    Health Care

    SEC Form SCHEDULE 13G filed by Medline Inc.

    SCHEDULE 13G - Medline Inc. (0002046386) (Subject)

    12/29/25 4:20:17 PM ET
    $MDLN
    Medical/Dental Instruments
    Health Care

    Medline Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Material Modification to Rights of Security Holders, Leadership Update

    8-K - Medline Inc. (0002046386) (Filer)

    12/22/25 4:48:32 PM ET
    $MDLN
    Medical/Dental Instruments
    Health Care

    $MDLN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Bx Mozart Ml-1 Holdco L.P. claimed ownership of 125,739,507 shares and claimed ownership of 62,871,125 units of Class B Common Stock (SEC Form 3)

    3 - Medline Inc. (0002046386) (Issuer)

    1/26/26 4:30:05 PM ET
    $MDLN
    Medical/Dental Instruments
    Health Care

    Former 10% Owners Tc Group Viii, L.L.C. disposed of 94,348,666 shares (SEC Form 4)

    4 - Medline Inc. (0002046386) (Issuer)

    1/21/26 4:30:24 PM ET
    $MDLN
    Medical/Dental Instruments
    Health Care

    New insider Cp Circle Ml Holdco Gp, Llc claimed ownership of 111,994,953 shares and claimed ownership of 55,557,381 units of Class B Common Stock (SEC Form 3)

    3 - Medline Inc. (0002046386) (Issuer)

    1/21/26 4:30:14 PM ET
    $MDLN
    Medical/Dental Instruments
    Health Care

    $MDLN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Tigress Financial initiated coverage on Medline with a new price target

    Tigress Financial initiated coverage of Medline with a rating of Buy and set a new price target of $55.00

    2/5/26 10:03:24 AM ET
    $MDLN
    Medical/Dental Instruments
    Health Care

    BTIG Research reiterated coverage on Medline with a new price target

    BTIG Research reiterated coverage of Medline with a rating of Buy and set a new price target of $55.00 from $50.00 previously

    1/21/26 1:17:48 PM ET
    $MDLN
    Medical/Dental Instruments
    Health Care

    Citigroup initiated coverage on Medline with a new price target

    Citigroup initiated coverage of Medline with a rating of Buy and set a new price target of $48.00

    1/12/26 10:44:50 AM ET
    $MDLN
    Medical/Dental Instruments
    Health Care

    $MDLN
    Financials

    Live finance-specific insights

    View All

    Medline to report fourth quarter and full year 2025 results on February 25, 2026

    NORTHFIELD, Ill., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Medline Inc. ("Medline") (NASDAQ:MDLN) today announced that it plans to report fourth quarter and full year 2025 financial results on Wednesday, February 25, 2026. A press release and supplemental materials will be issued before the market opens. The company will host a webcast and conference call at 9:30am ET/ 8:30am CT to discuss the financial results. Information about Medline's financial results, including a link to the live webcast, will be available on the Events page of Medline's Investor Relations website at ir.medline.com. A replay of the webcast will be available following the event through the same website. About MedlineMedli

    1/28/26 9:00:00 AM ET
    $MDLN
    Medical/Dental Instruments
    Health Care